The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users

Addiction

Volumn 107, Issue 7, 2012, Pages 1318-1327

  Bruneau, Julie ^a,b   Roy, Élise ^c,d   Arruda, Nelson ^e   Zang, Geng ^a   Jutras Aswad, Didier ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d Gouvernement du Quebec   (Canada)

^e NONE

Author keywords

Cohort study; HCV incidence; Illicit opioid misuse; Injection drug use; Injection risk behaviour; Prescription opioid

Indexed keywords

NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG; STREET DRUG;

ADULT; ARTICLE; CANADA; DRUG ABUSE; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MALE; OPIATE ADDICTION; PROSPECTIVE STUDY; STATISTICS; SUBSTANCE ABUSE;

ADULT; ANALGESICS, OPIOID; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; NEEDLE SHARING; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES; QUEBEC; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84861941279     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03803.x     Document Type: Article

References (54)

1. International Narcotics Control Board. Report of the International Narcotics Control Board for 2010. United Nations Publication. 2011. Available at: (accessed 8 July 2011; archived by WebCite® at ).
2. Substance Abuse and Mental Health Administration (SAMHSA), US Department of Health and Human Services, Office of Applied Studies. Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. 2008. Available at: (accessed 8 July 2011; archived by WebCite® at ).
3. Cleland C. M., Rosenblum A., Fong C., Maxwell C. Age differences in heroin and prescription opioid abuse among enrolees into opioid treatment programs. Subst Abuse Treat Prev Policy 2011; 6: 11-9.
4. Drug and Alcohol Treatment Information System (DATIS), Centre for Addiction and Mental Health. Substance abuse statistical tables. 2010. Available at: (accessed 8 July 2011; archived by WebCite® at ).
5. Davis W. R., Johnson B. D. Prescription opioid use, misuse, and diversion among street drug users in New York city. Research Support, NIH, Extramural Research Support, non-US Government. Drug Alcohol Depend 2008; 92: 267-76.
6. Surratt H. L., Inciardi J. A., Kurtz S. P. Prescription opioid abuse among drug-involved street-based sex workers. Research Support, NIH, Extramural. J Opioid Manag 2006; 2: 283-9.
7. Fischer B., Rehm J., Patra J., Firestone Cruz M. Changes in illicit opioid use across Canada. Can Med Assoc J 2006; 175: 1385-7.
8. Monga N., Rehm J., Fischer B., Brissette S., Bruneau J., El-Guebaly N. etal. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Depend 2007; 88: 1-8.
9. Degenhardt L., Black E., Breen C., Bruno R., Kinner S., Roxburgh A. etal. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006; 25: 403-12.
10. Havens J. R., Oser C. B., Leukefeld C. G., Webster J. M., Martin S. S., O'Connell D. J. etal. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Comparative Study Research Support, NIH, Extramural. Am J Drug Alcohol Abuse 2007; 33: 309-17.
11. Parent R., Alary M., Morissette C., Roy E., Leclerc P., Allard P. R. Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection-Épidémiologie du VIH de 1995 à 2008-Épidémiologie du VHC de 2003 à 2008 [Surveillance of infectious diseases among injection drug users-Epidemiology of HIV from 1995 to 2008-Epidemiology of HCV from 2003 to 2008.]. Institut National de Santé Publique du Québec. 2009. Available at: (accessed 8 July 2011; archived by WebCite® at ).
12. Roy E., Arruda N., Vaillancourt E., Boivin J. F., Morissette C., Leclerc P. etal. Drug use patterns in the presence of crack in downtown Montreal. Drug Alcohol Rev 2012; 31: 72-80.
13. Baldo V., Baldovin T., Trivello R., Floreani A. Epidemiology of HCV infection. Curr Pharm Des 2008; 14: 1646-54.
14. Wasley A., Grytdal S., Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
15. Wu H. X., Wu J., Wong T., Donaldson T., Dinner K., Andonov A. etal. Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004. Scand J Infect Dis 2006; 38: 482-9.
16. Razali K., Thein H. H., Bell J., Cooper-Stanbury M., Dolan K., Dore G. etal. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91: 228-35.
17. Alter M. J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
18. Tyndall M. W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M. V. etal. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003; 17: 887-93.
19. Miller C. L., Johnston C., Spittal P. M., Li K., Laliberte N., Montaner J. S. etal. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-42.
20. Bruneau J., Daniel M., Kestens Y., Abrahamowicz M., Zang G. Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: results from a cohort study. Int J Drug Policy 2010; 21: 477-84.
21. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J. F., Parent R. etal. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007; 18: 23-7.
22. Firestone Cruz M., Fischer B., Patra J., Kalousek K., Newton-Taylor B., Rehm J. etal. Prevalence and associated factors of hepatitis C infection (HCV) in a multi-site Canadian population of illicit opioid and other drug users (OPICAN). Can J Public Health 2007; 98: 130-3.
23. Craib K. J., Spittal P. M., Patel S. H., Christian W. M., Moniruzzaman A., Pearce M. E. etal. Prevalence and incidence of hepatitis C virus infection among Aboriginal young people who use drugs: results from the Cedar Project. Open Med 2009; 3: e220-227.
24. De P., Roy E., Boivin J. F., Cox J., Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepatol 2008; 15: 279-92.
25. Hagan H., Pouget E. R., Williams I. T., Garfein R. L., Strathdee S. A., Hudson S. M. etal. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis 2010; 201: 378-85.
26. Thorpe L. E., Ouellet L. J., Hershow R., Bailey S. L., Williams I. T., Williamson J. etal. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-53.
27. Koester S. K. The context of risk: ethnographic contributions to the study of drug use and HIV. NIDA Res Monogr 1994; 143: 202-17.
28. Roy E., Arruda N., Bourgois P. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse 2011; 46: 1142-50.
29. Bruneau J., Lamothe F., Soto J., Lachance N., Vincelette J., Vassal A. etal. Sex-specific determinants of HIV infection among injection drug users in Montreal. Can Med Assoc J 2001; 164: 767-73.
30. Bruneau J., Daniel M., Kestens Y., Zang G., Genereux M. Associations between HIV-related injection behaviour and distance to and patterns of utilisation of syringe-supply programmes. J Epidemiol Community Health 2008; 62: 804-10.
31. Klein J. P., Moeschberger M. L. Survival Analysis. Techniques for Censored and Truncated Data. New York: Springer-Verlag; 1997.
32. Hosmer D. J., Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley; 1999, p. 386.
33. Roy E., Boudreau J. F., Boivin J. F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 2009; 102: 158-61.
34. Patrick D. M., Tyndall M. W., Cornelisse P. G., Li K., Sherlock C. H., Rekart M. L. etal. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J 2001; 165: 889-95.
35. Hagan H., Thiede H., Des Jarlais D. C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004; 15: 543-9.
36. Talu A., Rajaleid K., Abel-Ollo K., Ruutel K., Rahu M., Rhodes T. etal. HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: implications for intervention. Int J Drug Policy 2010; 21: 56-63.
37. Maher L., Li J., Jalaludin B., Wand H., Jayasuriya R., Dixon D. etal. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. Drug Alcohol Depend 2007; 89: 244-50.
38. Wood E., Tyndall M. W., Spittal P. M., Li K., Anis A. H., Hogg R. S. etal. Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. Can Med Assoc J 2003; 168: 165-9.
39. Topp L., Day C., Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend 2003; 70: 275-86.
40. Hagan H., Thiede H., Weiss N. S., Hopkins S. G., Duchin J. S., Alexander E. R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.
41. Hahn J. A., Page-Shafer K., Lum P. J., Bourgois P., Stein E., Evans J. L. etal. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-64.
42. Mehta S. H., Vogt S. L., Srikrishnan A. K., Vasudevan C. K., Murugavel K. G., Saravanan S. etal. Epidemiology of hepatitis C virus infection and liver disease among injection drug users (IDUs) in Chennai, India. Indian J Med Res 2010; 132: 706-14.
43. Bourgois P. The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse 1998; 33: 2323-51.
44. Bourgois P., Schonberg J. Righteous Dopefiend. Berkeley, CA: University of California Press; 2009.
45. McGovern B. H., Wurcel A., Kim A. Y., Schulze zur Wiesch J., Bica I., Zaman M. T. etal. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006; 42: 1663-70.
46. van Haastrecht H. J., Bax J. S., van den Hoek A. A. High rates of drug use, but low rates of HIV risk behaviours among injecting drug users during incarceration in Dutch prisons. Addiction 1998; 93: 1417-25.
47. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Jones S. etal. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepatol 2005; 12: 655-62.
48. Garten R. J., Lai S., Zhang J., Liu W., Chen J., Vlahov D. etal. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-8.
49. Mansson A. S., Moestrup T., Nordenfelt E., Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000; 32: 253-8.
50. Brunton C., Kemp R., Raynel P., Harte D., Baker M. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. NZ Med J 2000; 113: 98-101.
51. Bruneau J., Daniel M., Abrahamowicz M., Zang G., Lamothe F., Vincelette J. Trends in HIV incidence and risk behavior among injection drug users in Montreal, Canada: a 16-year longitudinal study. Am J Epidemiol 2011; 173: 1049-58.
52. Bourgois P., Bruneau J. Needle exchange, HIV infection, and the politics of science: confronting Canada's cocaine injection epidemic with participant observation. Med Anthropol 2000; 18: 325-50.
53. Comité permanent de lutte à la toxicomanie, Ministère de la santé et des services sociaux (MSSS). Le point sur la situation de la toxicomanie au Québec en l'an 2000 [Drug addiction Update in Quebec in the year 2000.]. MSSS, Québec. 2000. Available at: (accessed 8 July 2011; archived by WebCite® at ).
54. De Irala J., Bigelow C., McCusker J., Hindin R., Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol 1996; 143: 725-32.